product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Myosin Light Chain 2 (D18E2) Rabbit mAb
catalog :
8505
clonality :
monoclonal
host :
rabbit
conjugate :
nonconjugated
clone name :
D18E2
reactivity :
human, mouse, rat
application :
western blot
more info or order :
citations: 8
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
| |
| |
| |
| |
| |
product information
SKU :
8505S
Product-Name :
Myosin Light Chain 2 (D18E2) Rabbit mAb
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R
Applications :
Western blot
Product-Category :
Cytoskeletal Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
18
Host :
Rabbit
Target :
Myosin Light Chain 2 smooth muscle isoform
Primary-Protein :
MRLC1
Alt-Names :
20 kDa myosin light chain,LC20,MGC3505,MLC-2C,MLC2,MRLC1,MYL9,MYRL2,Myosin RLC,Myosin regulatory light chain 2, smooth muscle isoform,Myosin regulatory light chain 9,Myosin regulatory light chain MRLC1,Myosin regulatory light polypeptide 9,myosin regulatory light chain 1,myosin, light chain 9, regulatory,myosin, light polypeptide 9, regulatory
more info or order :
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.
review
product type
related products
browse more products
questions and comments